227 related articles for article (PubMed ID: 26448580)
1. The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro.
Dupuis ML; Fiori V; Soriani A; Ricci B; Dominici S; Moricoli D; Ascione A; Santoni A; Magnani M; Cianfriglia M
J Immunother; 2015; 38(9):357-70. PubMed ID: 26448580
[TBL] [Abstract][Full Text] [Related]
2. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival.
Ullrich N; Heinemann A; Nilewski E; Scheffrahn I; Klode J; Scherag A; Schadendorf D; Singer BB; Helfrich I
Cancer Res; 2015 May; 75(9):1897-907. PubMed ID: 25744717
[TBL] [Abstract][Full Text] [Related]
3. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1.
Stern N; Markel G; Arnon TI; Gruda R; Wong H; Gray-Owen SD; Mandelboim O
J Immunol; 2005 Jun; 174(11):6692-701. PubMed ID: 15905509
[TBL] [Abstract][Full Text] [Related]
5. Systemic dysregulation of CEACAM1 in melanoma patients.
Markel G; Ortenberg R; Seidman R; Sapoznik S; Koren-Morag N; Besser MJ; Bar J; Shapira R; Kubi A; Nardini G; Tessone A; Treves AJ; Winkler E; Orenstein A; Schachter J
Cancer Immunol Immunother; 2010 Feb; 59(2):215-30. PubMed ID: 19633846
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.
Ortenberg R; Sapir Y; Raz L; Hershkovitz L; Ben Arav A; Sapoznik S; Barshack I; Avivi C; Berkun Y; Besser MJ; Ben-Moshe T; Schachter J; Markel G
Mol Cancer Ther; 2012 Jun; 11(6):1300-10. PubMed ID: 22466331
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
Markel G; Seidman R; Stern N; Cohen-Sinai T; Izhaki O; Katz G; Besser M; Treves AJ; Blumberg RS; Loewenthal R; Mandelboim O; Orenstein A; Schachter J
J Immunol; 2006 Nov; 177(9):6062-71. PubMed ID: 17056532
[TBL] [Abstract][Full Text] [Related]
8. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.
Fantini M; David JM; Annunziata CM; Morelli MP; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2020 Apr; 35(3):190-198. PubMed ID: 31928422
[No Abstract] [Full Text] [Related]
9. Inhibition of NKp30- and 2B4-mediated NK cell activation by evolutionary different human and bovine CEACAM1 receptors.
Merkt W; Urlaub D; Meinke S; Kammerer R; Watzl C
Eur J Immunol; 2015 Jul; 45(7):2134-42. PubMed ID: 25824372
[TBL] [Abstract][Full Text] [Related]
10. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells.
Markel G; Gruda R; Achdout H; Katz G; Nechama M; Blumberg RS; Kammerer R; Zimmermann W; Mandelboim O
J Immunol; 2004 Sep; 173(6):3732-9. PubMed ID: 15356119
[TBL] [Abstract][Full Text] [Related]
11. The tumour suppressor gene CEACAM1 is completely but reversibly downregulated in renal cell carcinoma.
Kammerer R; Riesenberg R; Weiler C; Lohrmann J; Schleypen J; Zimmermann W
J Pathol; 2004 Nov; 204(3):258-67. PubMed ID: 15476270
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
[TBL] [Abstract][Full Text] [Related]
13. Isolation of a new human scFv antibody recognizing a cell surface binding site to CEACAM1. Large yield production, purification and characterization in E. coli expression system.
Moricoli D; Laguardia ME; Carbonella DC; Balducci MC; Dominici S; Fiori V; Serafini G; Flego M; Cianfriglia M; Magnani M
Protein Expr Purif; 2014 Jan; 93():38-45. PubMed ID: 24184403
[TBL] [Abstract][Full Text] [Related]
14. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.
Markel G; Seidman R; Cohen Y; Besser MJ; Sinai TC; Treves AJ; Orenstein A; Berger R; Schachter J
Immunology; 2009 Feb; 126(2):186-200. PubMed ID: 18557789
[TBL] [Abstract][Full Text] [Related]
15. CEACAM1 promotes melanoma cell growth through Sox-2.
Ortenberg R; Galore-Haskel G; Greenberg I; Zamlin B; Sapoznik S; Greenberg E; Barshack I; Avivi C; Feiler Y; Zan-Bar I; Besser MJ; Azizi E; Eitan F; Schachter J; Markel G
Neoplasia; 2014 May; 16(5):451-60. PubMed ID: 24931667
[TBL] [Abstract][Full Text] [Related]
16. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.
Sapoznik S; Ortenberg R; Schachter J; Markel G
Curr Top Med Chem; 2012; 12(1):3-10. PubMed ID: 22196267
[TBL] [Abstract][Full Text] [Related]
17. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells.
Banerjee P; Feuer G; Barker E
J Virol; 2007 Sep; 81(18):9707-17. PubMed ID: 17609265
[TBL] [Abstract][Full Text] [Related]
18. In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma.
Gandoglia I; Ivaldi F; Carrega P; Armentani E; Ferlazzo G; Mancardi G; Kerlero de Rosbo N; Uccelli A; Laroni A
Immunol Lett; 2017 Jan; 181():109-115. PubMed ID: 27919749
[TBL] [Abstract][Full Text] [Related]
19. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients.
Markel G; Achdout H; Katz G; Ling KL; Salio M; Gruda R; Gazit R; Mizrahi S; Hanna J; Gonen-Gross T; Arnon TI; Lieberman N; Stren N; Nachmias B; Blumberg RS; Steuer G; Blau H; Cerundolo V; Mussaffi H; Mandelboim O
Eur J Immunol; 2004 Aug; 34(8):2138-48. PubMed ID: 15259011
[TBL] [Abstract][Full Text] [Related]
20. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.
Schmohl JU; Gleason MK; Dougherty PR; Miller JS; Vallera DA
Target Oncol; 2016 Jun; 11(3):353-61. PubMed ID: 26566946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
